Literature DB >> 23744883

Increased levels of cell-free human placental lactogen mRNA at 28-32 gestational weeks in plasma of pregnant women with placenta previa and invasive placenta.

Akihiro Kawashima1, Akihiko Sekizawa, Walter Ventura, Keiko Koide, Kyouko Hori, Takashi Okai, Yoshida Masashi, Kenichi Furuya, Yoshifumi Mizumoto.   

Abstract

We compared the levels of cell-free human placental lactogen (hPL) messenger RNA (mRNA) in maternal plasma at 28 to 32 weeks of gestation between women with diagnosis of placenta previa or invasive placenta and women with an uneventful pregnancy. Sensitivity and specificity of hPL mRNA for the prediction of invasive placenta were further explored. Plasma hPL mRNA were quantified by real-time reverse-transcriptase polymerase chain reaction in women with placenta previa (n = 13), invasive placenta (n = 5), and normal pregnancies (n = 92). Median (range) hPL mRNA was significantly higher in women with placenta previa, 782 (10-2301) copies/mL of plasma, and in those with invasive placenta, 615 (522-2102) copies/mL of plasma, when compared to normal pregnancies, 90 (4-4407) copies/mL of plasma, P < .01 and P < .05, respectively. We found a sensitivity of 100% and a specificity of 61.5% for the prediction of invasive placenta among women with placenta previa. In conclusion, expression of hPL mRNA is increased in plasma of women with placenta previa and invasive placenta at 28 to 32 weeks of gestation.

Entities:  

Keywords:  cell-free RNA; hPL; placenta accreta; placenta previa

Mesh:

Substances:

Year:  2013        PMID: 23744883      PMCID: PMC3879989          DOI: 10.1177/1933719113492209

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  18 in total

1.  Presence of fetal RNA in maternal plasma.

Authors:  L L Poon; T N Leung; T K Lau; Y M Lo
Journal:  Clin Chem       Date:  2000-11       Impact factor: 8.327

2.  Placenta increta: Postpartum monitoring of plasma cell-free fetal DNA.

Authors:  Masatoshi Jimbo; Akihiko Sekizawa; Yumi Sugito; Ryu Matsuoka; Kiyotake Ichizuka; Hiroshi Saito; Takashi Okai
Journal:  Clin Chem       Date:  2003-09       Impact factor: 8.327

3.  Stability of endogenous and added RNA in blood specimens, serum, and plasma.

Authors:  Nancy B Y Tsui; Enders K O Ng; Y M Dennis Lo
Journal:  Clin Chem       Date:  2002-10       Impact factor: 8.327

4.  Circulating corticotropin-releasing hormone mRNA in maternal plasma: relationship with gestational age and severity of preeclampsia.

Authors:  Antonio Farina; Carol W M Chan; Rossa W K Chiu; Nancy B Y Tsui; Paolo Carinci; Manuela Concu; Irina Banzola; Nicola Rizzo; Y M Dennis Lo
Journal:  Clin Chem       Date:  2004-10       Impact factor: 8.327

5.  Creatine kinase as a biochemical marker in diagnosis of placenta increta and percreta.

Authors:  E Ophir; R Tendler; M Odeh; S Khouri; M Oettinger
Journal:  Am J Obstet Gynecol       Date:  1999-04       Impact factor: 8.661

6.  Immunocytochemical localization of placental lactogen and chorionic gonadotropin in the normal placenta and trophoblastic tumors, with emphasis on intermediate trophoblast and the placental site trophoblastic tumor.

Authors:  R J Kurman; R H Young; H J Norris; C S Main; W D Lawrence; R E Scully
Journal:  Int J Gynecol Pathol       Date:  1984       Impact factor: 2.762

7.  Sonographic detection of placenta accreta in the second and third trimesters of pregnancy.

Authors:  Christine H Comstock; Joseph J Love; Richard A Bronsteen; Wesley Lee; Ivana M Vettraino; Raywin R Huang; Robert P Lorenz
Journal:  Am J Obstet Gynecol       Date:  2004-04       Impact factor: 8.661

8.  Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals.

Authors:  Enders K O Ng; Nancy B Y Tsui; Nicole Y L Lam; Rossa W K Chiu; Simon C H Yu; S C Cesar Wong; Elena S F Lo; Timothy H Rainer; Philip J Johnson; Y M Dennis Lo
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

9.  Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.

Authors:  C Zelop; A Nadel; F D Frigoletto; S Pauker; M MacMillan; B R Benacerraf
Journal:  Obstet Gynecol       Date:  1992-10       Impact factor: 7.661

10.  Committee opinion no. 529: placenta accreta.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-07       Impact factor: 7.661

View more
  4 in total

Review 1.  Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum.

Authors:  Tianyue Zhang; Shaowei Wang
Journal:  Front Med (Lausanne)       Date:  2022-05-30

2.  The expression and biological function of chemokine CXCL12 and receptor CXCR4/CXCR7 in placenta accreta spectrum disorders.

Authors:  Yu Long; Yonghua Jiang; Jingjing Zeng; Yiwu Dang; Yue Chen; Jueying Lin; Hongwei Wei; Hongwei Xia; Junqing Long; Cuizhen Luo; Zhiwei Chen; Yaling Huang; MuJun Li
Journal:  J Cell Mol Med       Date:  2020-01-28       Impact factor: 5.310

Review 3.  Manual removal of the placenta after vaginal delivery: an unsolved problem in obstetrics.

Authors:  Fiona Urner; Roland Zimmermann; Alexander Krafft
Journal:  J Pregnancy       Date:  2014-04-09

4.  Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study.

Authors:  Alexander Schwickert; Frédéric Chantraine; Loreen Ehrlich; Wolfgang Henrich; Mustafa Zelal Muallem; Andreas Nonnenmacher; Philippe Petit; Katharina Weizsäcker; Thorsten Braun
Journal:  Reprod Sci       Date:  2020-10-06       Impact factor: 3.060

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.